Mometasona Gsp (Mometasone Furoate)

Mometasone furoate nasal spray acts on inflammatory pathways of the nasal mucosa to relieve symptoms of several nasal disorders.

• Allergic rhinitis: Reduces nasal congestion, itching, sneezing and rhinorrhea associated with seasonal or perennial allergies.
• Non‑allergic rhinitis: Improves nasal airflow and decreases irritation caused by non‑allergic triggers.
• Nasal polyps: Shrinks polyp size and alleviates obstruction, improving breathing and sense of smell.

• Mometasone furoate binds to intracellular glucocorticoid receptors in nasal epithelial cells, forming a complex that translocates to the nucleus and modulates gene transcription. This action suppresses pro‑inflammatory cytokine production, reduces vascular permeability, and inhibits leukocyte infiltration, leading to decreased nasal mucosal inflammation.

Mometasone furoate nasal spray may cause local and systemic adverse reactions.

Common Side Effects

• Nasal irritation or burning sensation
• Headache
• Epistaxis (nosebleed)
• Throat irritation or dryness
• Altered taste or bitter taste
• Cough

Serious or Rare Side Effects

• Nasal septal perforation
• Severe or prolonged epistaxis
• Visual disturbances (e.g., cataracts, glaucoma)
• Adrenal suppression with prolonged high‑dose use
• Opportunistic fungal infection of the nasal passages
• Systemic corticosteroid effects such as hyperglycemia

Before initiating therapy, consider the following safety measures.

• Assess for active nasal infection: Avoid use if bacterial, viral, or fungal infection is present.
• Evaluate history of glaucoma or cataracts: Monitor intra‑ocular pressure during treatment.
• Review systemic corticosteroid use: Minimize combined systemic exposure.
• Counsel patients on proper spray technique to reduce local irritation.
• Store at ambient temperature: Keep below 25°C in the original container, protect from moisture and direct sunlight.

Mometasone furoate may interact with other medications that affect corticosteroid metabolism or increase systemic exposure.

Major Interactions (Avoid)

• Concurrent use of other intranasal corticosteroids: Increases risk of local and systemic side effects.
• Systemic glucocorticoids: Potentiates systemic corticosteroid effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May raise systemic mometasone levels.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): May modestly increase exposure.
• Antifungal azoles used systemically: Monitor for signs of adrenal suppression.
• Ritonavir or other protease inhibitors: Observe for enhanced systemic effects.